AR017212A1 - Composiciones farmaceuticas de benzopirano y piridopirano, procedimiento para su preparacion y el uso de dicha composicion para la elaboracion de unmedicamento - Google Patents

Composiciones farmaceuticas de benzopirano y piridopirano, procedimiento para su preparacion y el uso de dicha composicion para la elaboracion de unmedicamento

Info

Publication number
AR017212A1
AR017212A1 ARP980106367A ARP980106367A AR017212A1 AR 017212 A1 AR017212 A1 AR 017212A1 AR P980106367 A ARP980106367 A AR P980106367A AR P980106367 A ARP980106367 A AR P980106367A AR 017212 A1 AR017212 A1 AR 017212A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
alkoxy
substituted
cyano
Prior art date
Application number
ARP980106367A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR017212A1 publication Critical patent/AR017212A1/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C17/00—Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls
    • B02C17/04—Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls with unperforated container
    • B02C17/06—Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls with unperforated container with several compartments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C17/00—Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls
    • B02C17/18—Details
    • B02C17/20—Disintegrating members
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C17/00—Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls
    • B02C17/18—Details
    • B02C17/22—Lining for containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composicion farmacéutica de benzopirano y piridopirano, caracterizado porque comprende un compuesto de Formula (I) o Formula (II) en la cual: o bien Yes N y R1 es hidrogeno, o Y es C-R1 en donde: o bien uno de R1 y R2 es hidrogeno y el otro sese lecciona entre la clase de hidrogeno, cicloalquilo C1-3alquilo C1-6 opcionalmente interrumpido por oxígeno o sustituido con hidroxi, alcoxi, C1-6, o aminocarbonilo sustituido, alquil C1-6, carbonilo, alcoxi C1-6-carbonilo, alquilC1-6-carboniloxi, a lcoxi C1-6,nitro, ciano, halo trifluorometilo, CF3S o un grupo CF3-A- en el que A es -CF3-, -CO-, CH2- o CH(OH),trifluorometoxi, alquil C1-6-sulfinilo, alquil C1-6-sulfonilo, alcoxi C1-6-sulfinilo, alcoxi C1-6-sulfonilo, arilo,heteroarilo, arilcarbo nilo, heteroarilcarbonilo,arilsulfinilo,heteroarilsulfinilo,arilsulfonilo,heteroarilsulfonilo,en los que cualquier resto aromático está opcionalmente sustituido, alquil C1-6-carbonilamino, alcoxi C1-6 - carbonilamino, alquilC1-6 - tiocarbonilo, alco xi C1-6-tiocarbonilo, alquil C1-6- tiocarboniloxi, 1-mercapto-alquilo C2-7, formiloo aminosulfinilo, aminosulfonilo o aminocarbonilo, estando opcionalmente sustituido cualquier resto amino con uno o dos grupos alquilo C1-6o alquil C1-6-sulfinilamino , alquil C1-6-sulfonilamino, alcoxi C1-6- sulfinilamino o alcoxi C1-6-sulfonilamino, o etileno terminalmente sustituido con alquil C21-6-carbonilonitro, ciano, o -C(alquil C1-6)NOH o -C(alquilo C1-6) NNH3, o uno de R1 yR2 es nitro, ciano, alquil C1- 3-carbonilo y el otro es metoxi o amino opcionalmentesustituido con uno o dos alquilo C1-6 o alcanoilo C2-7; uno de R3 y R4 es hidrogeno o alquilo C1-4 y el otro es alquilo C1-4 o R3 y R4 conjuntamente sonpolimetilenoC2-5; R5 es alquil C1-6- carbon iloxi, benzoiloxi, ONO2, benciloxi, feniloxi o alcoxi C1-6 y R6 y R9 son hidrogeno o R5 es hidroxi y R6 eshidrogeno o alquilo C1-2 y R7 es hidrogeno; R7 es fluorofenilo; R8 es hidrogeno o alquilo C1-6; siendo trans elgrupo R9-N-CO-R, respecto al gru po R5; y X esoxígeno o NR10, en donde R10 es hidrogeno o alquilo C1-6; y la formula II en la cual: o bien Y es N y R2 es hidrogeno, o Y es C-R1; en donde: o bien Y es N y
ARP980106367A 1997-12-16 1998-12-15 Composiciones farmaceuticas de benzopirano y piridopirano, procedimiento para su preparacion y el uso de dicha composicion para la elaboracion de unmedicamento AR017212A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9726543.3A GB9726543D0 (en) 1997-12-16 1997-12-16 Novel compositions

Publications (1)

Publication Number Publication Date
AR017212A1 true AR017212A1 (es) 2001-08-22

Family

ID=10823680

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980106367A AR017212A1 (es) 1997-12-16 1998-12-15 Composiciones farmaceuticas de benzopirano y piridopirano, procedimiento para su preparacion y el uso de dicha composicion para la elaboracion de unmedicamento

Country Status (32)

Country Link
EP (2) EP1338274A1 (es)
JP (1) JP2002508310A (es)
KR (1) KR20010033149A (es)
CN (2) CN1475206A (es)
AP (1) AP2000001837A0 (es)
AR (1) AR017212A1 (es)
AT (1) ATE260094T1 (es)
AU (1) AU743155B2 (es)
BG (1) BG104596A (es)
BR (1) BR9813602A (es)
CA (1) CA2314968A1 (es)
DE (1) DE69821978T2 (es)
DZ (1) DZ2677A1 (es)
EA (1) EA003732B1 (es)
ES (1) ES2216350T3 (es)
GB (1) GB9726543D0 (es)
HU (1) HUP0100384A3 (es)
ID (1) ID24930A (es)
IL (1) IL136664A0 (es)
MA (1) MA24721A1 (es)
MY (1) MY132978A (es)
NO (1) NO20003073L (es)
NZ (1) NZ504991A (es)
OA (1) OA11429A (es)
PE (1) PE20000114A1 (es)
PL (1) PL341339A1 (es)
SK (1) SK9132000A3 (es)
TR (1) TR200001792T2 (es)
TW (1) TW200305442A (es)
UY (1) UY25307A1 (es)
WO (1) WO1999030687A1 (es)
ZA (1) ZA9811502B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE274341T1 (de) 1995-02-24 2004-09-15 Elan Pharma Int Ltd Nanopartikel-dispersionen enthaltende aerosole
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
CA2413330A1 (en) * 2000-06-28 2002-01-03 Smithkline Beecham P.L.C. Wet milling process
GB0112497D0 (en) * 2001-05-22 2001-07-11 Smithkline Beecham Plc Formulation
GB0127805D0 (en) 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
KR20080066977A (ko) 2005-11-10 2008-07-17 더루우브리졸코오포레이션 분산체의 제조방법
US20110319482A1 (en) * 2008-06-05 2011-12-29 Peter Blower Novel treatments
WO2009147442A1 (en) * 2008-06-05 2009-12-10 Minster Research Limited Novel treatments
AU2010325755A1 (en) * 2009-12-03 2012-06-21 Proximagen Ltd Treatment of infectious diseases
RU2012124837A (ru) * 2009-12-03 2014-01-10 Проксимэджен ЛТД Лечение аллодинии и гипералгезии
SI2471513T1 (sl) * 2010-12-28 2015-10-30 Lek Pharmaceuticals D.D. Postopek za pripravo zdravilne učinkone (API) v obliki pelet
WO2016157061A1 (en) * 2015-03-31 2016-10-06 Wockhardt Limited Aseptic wet milling process for paliperidone palmitate

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5065946A (en) * 1988-07-21 1991-11-19 Matsushita Electric Industrial Co., Ltd. Media agitating mill and method for milling ceramic powder
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
NZ248813A (en) * 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
NZ258611A (en) * 1992-12-11 1997-07-27 Smithkline Beecham Plc 4-benzoyl(or heteroarylcarbonyl)amino-3,4-dihydro- 3-hydroxy-2h-benzo[b]pyran derivatives;benzopyrano[4,3-d]oxazole intermediates
DE69524871T2 (de) * 1994-06-10 2002-08-22 Smithkline Beecham Plc Benzopyrans und deren verwendung als therapeutische mittel
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5518738A (en) * 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
DE19614295A1 (de) * 1995-04-21 1996-10-24 Friedrich Dr Ing Vock Verfahren und Vorrichtung zum Nassmahlen und Dispergieren von Feststoffpartikeln in Flüssigkeiten

Also Published As

Publication number Publication date
CN1284865A (zh) 2001-02-21
GB9726543D0 (en) 1998-02-11
DE69821978T2 (de) 2004-12-23
EP1338274A1 (en) 2003-08-27
NO20003073D0 (no) 2000-06-15
MA24721A1 (fr) 1999-07-01
BG104596A (en) 2001-04-30
ATE260094T1 (de) 2004-03-15
EA003732B1 (ru) 2003-08-28
CA2314968A1 (en) 1999-06-24
JP2002508310A (ja) 2002-03-19
DE69821978D1 (de) 2004-04-01
ID24930A (id) 2000-08-31
WO1999030687A1 (en) 1999-06-24
PL341339A1 (en) 2001-04-09
PE20000114A1 (es) 2000-04-30
OA11429A (en) 2004-04-26
ES2216350T3 (es) 2004-10-16
AU743155B2 (en) 2002-01-17
NO20003073L (no) 2000-08-10
MY132978A (en) 2007-10-31
SK9132000A3 (en) 2001-01-18
EP1037612A1 (en) 2000-09-27
TW200305442A (en) 2003-11-01
HUP0100384A3 (en) 2002-04-29
NZ504991A (en) 2002-11-26
ZA9811502B (en) 2000-06-15
AP2000001837A0 (en) 2000-06-30
CN1475206A (zh) 2004-02-18
IL136664A0 (en) 2001-06-14
EP1037612B1 (en) 2004-02-25
DZ2677A1 (fr) 2003-03-29
BR9813602A (pt) 2002-01-22
AU2272499A (en) 1999-07-05
HUP0100384A2 (hu) 2001-12-28
UY25307A1 (es) 2001-08-27
EA200000664A1 (ru) 2000-12-25
TR200001792T2 (tr) 2000-11-21
KR20010033149A (ko) 2001-04-25

Similar Documents

Publication Publication Date Title
AR017212A1 (es) Composiciones farmaceuticas de benzopirano y piridopirano, procedimiento para su preparacion y el uso de dicha composicion para la elaboracion de unmedicamento
BR9506828A (pt) Composição contendo nebivolol micronizado
AR009128A1 (es) Un compuesto de 8-aril-1,7-naftiridina, composiciones farmaceuticas que lo comprenden, utilizacion de dicho compuesto para la fabricacion de medicamentos,procedimiento para la preparacion de tal compuesto y productos intermedios utilizados en dicha preparacion
AR040031A1 (es) Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen
PE20020476A1 (es) Derivados de glucopiranosiloxibencilbenceno y composiciones farmaceuticas que comprenden los mismos
AR013542A1 (es) Compuesto 5-azaquinoxalinico, composicion farmaceutica que lo comprende, metodo para sintetizarlo, metodo para modular la funcion de una serina/treoninaproteina-quinasa con dicho compuesto, metodo para identificar compuestos que modulan tal funcion y uso del mismo para preparar una composicion farma
ECSP055815A (es) Composición para el tratamiento de la infección por virus flaviviridae
GB2457416A (en) Directly photodefinable polymer compositions and methods thereof
AR247721A1 (es) Un procedimiento para la preparacion de compuestos de fenetanolamina y sus sales y solvatos farmaceuticamente aceptables
AR017796A1 (es) DERIVADOS DE 2-ARIL-8-OXODIHIDROPURINA, PROCEDIMIENTOS PARA PREPARARLOS, COMPUESTOS INTERMEDIARIOS DE APLICACIoN EN DICHOS PROCEDIMIENTOS, COMPOSICIONES FARMACEUTICAS, Y SU USO PARA LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ESTADOS DE ANSIEDAD.
ES2123654T3 (es) Carbapenems que contienen un grupo fenilo substituido con carboxi, procesos para su preparacion, productos intermedios y uso como antibioticos.
AR015487A1 (es) Uso de un compuesto de colesterol hidroxilado como agente reductor para preparar una composicion farmaceutica de utilidad en un metodo para inhibirla oxidacion de las lipoproteinas en un mamifero.
SE9600164D0 (sv) Stabilisatorkombination
ES8604189A1 (es) Un procedimiento para la preparacion de nuevos derivados delcromano
PT80689A (en) Process for the preparation of novel chroman and chromene compounds having pharmacological activity pharmaceutical compositions containing same and theier use in the treatment of mammals
AR014173A1 (es) Compuestos inhibidores del intercambio sodio/protones, de acil guanidina, utiles como agentes antianginales y cardioprotectores y las composicionesfarmaceuticas que los contienen
AR037940A1 (es) Compuestos antivirales de piridoquinoxalina
ATE115587T1 (de) 11-keto- oder hydroxy-3,5-diensteroiden als inhibitoren der steroid-5-alpha-reduktase.
AR035083A1 (es) Derivados azaheterociclilmetilicos de 7,8-dihidro-6h-5-oxa-1-aza-fenantreno, composiciones farmaceuticas, el uso de dichos derivados para la preparacion de un medicamento antidepresivo e intermediarios
ES2321307T8 (es) Uso de derivados de 4-ciano-naftaleno-1,8-dicarboximida y compuestos relacionados para proteger material orgánico de los efectos dañinos de la luz.
PE20011318A1 (es) Compuestos fenilo sustituidos inhibidores de la farnesiltransferasa
ES2189285T3 (es) Nuevas piranonas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
AR035003A1 (es) Derivados de propanolamina relacionados con acidos biliares, procedimiento para su preparacion, medicamentos conteniendo estos compuestos y su empleo para la preparacion de medicamentos
AR045912A1 (es) Composiciones farmaceuticas que contienen derivados de azetidina
AR031808A1 (es) 2-piridonas antimicrobianas, sus composiciones y usos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal